

Implementation Science Case Study:

Tuberculosis Guideline Observation and
Adherence in Low-income countries
(TB GOAL study)

Adithya Cattamanchi, MD

Advanced TB Diagnostics Research Course

July 7, 2011

acattamanchi@medsfgh.ucsf.edu

Outline

- Background
- Overview of study setting
- Progress to date: Aims 1-3
- Lessons Learned

Implementation defined

–noun

1. *any article used in some activity, esp. an instrument, tool, or utensil: agricultural implements.*
2. *an article of equipment, as household furniture, clothing, ecclesiastical vestments, or the like.*
3. *a means; agent: human beings as an implement of divine plan.*

–verb (used with object)


4. *to fulfill; perform; carry out: Once in office, he failed to implement his campaign promises.*
5. *to put into effect according to or by means of a definite plan or procedure.*
6. *to fill out or supplement.*
7. *to provide with implements.*

Implementation Science

- The **study of methods or strategies** to promote uptake of research findings into routine clinical practice
- NOT simply the validation of evidence-based practices or interventions in “real world” settings
- Contributes to an understanding of factors that help ensure similar outcomes in studies and in the “real world”

Estimated vs. Notified Cases

Case Detection Rate (%), 1995-2010



Reasons for low case detection rates

- Cases are diagnosed but not reported
- Cases do not seek care
- Cases seek care but are not diagnosed
 - Insensitive diagnostic tests
 - Poor TB evaluation practices


TB evaluation guidelines

International Standards for Tuberculosis Care

Standard 1. All persons with otherwise unexplained productive cough lasting 2-3 weeks or more should be evaluated for tuberculosis.

Standard 2. All patients who are capable of producing sputum suspected of having pulmonary tuberculosis should have at least two sputum specimens submitted for microscopic examination in a quality-assured laboratory.

Standard 8. All patients diagnosed with TB should receive an internationally accepted first-line treatment regimen.



- Initial aim: To describe adherence to ISTC at government health centers in Uganda
- Additional aims
 - To determine barriers to ISTC adherence
 - To develop and test a theory-driven intervention to increase ISTC adherence and TB case detection
- Overall hypothesis
 - Improving ISTC adherence will increase TB case detection at peripheral health centers in Uganda

Outline

- Background and specific aims
- **Overview of study setting**
- Methods/Results to date: Aims 1-3
- Conclusions and future directions

Study Setting: Uganda TB Surveillance Project



- Network of 6 government health centers
- Partners
 - Uganda Ministry of Health
 - Makerere University
- Electronic data collection (>100,000 patients/year)
- Web-interface to monitor indicators tied to ISTC

Patient Record Form

Clinic _____

Date _____	OPD Number _____	Patient's Last Name _____	First Name _____
Parish _____	Village _____	Age: _____ Yrs _____ Mos	Sex <input type="checkbox"/> Male <input type="checkbox"/> Female

History & Exam Findings

Fever or history of fever? Yes No History of cough > 2 weeks? Yes No (BOTH these questions must be completed)

<input type="checkbox"/> BS for Malaria <input type="checkbox"/> Pos <input type="checkbox"/> Neg	<input type="checkbox"/> HIV test <input type="checkbox"/> CTDR <input type="checkbox"/> CTR	<input type="checkbox"/> TB exam
Parasite density: _____ (if positive)	HIV Lab number: _____	1 st smear <input type="checkbox"/> Pos <input type="checkbox"/> Neg (today's date)
<input type="checkbox"/> RDT for Malaria <input type="checkbox"/> Pos <input type="checkbox"/> Neg		2 nd smear <input type="checkbox"/> Pos <input type="checkbox"/> Neg Date: _____
Malaria Lab number: _____		3 rd smear <input type="checkbox"/> Pos <input type="checkbox"/> Neg Date: _____
<input type="checkbox"/> Sput ordered - Results:	<input type="checkbox"/> Urinalysis ordered - Results:	TB Lab number: _____
		<input type="checkbox"/> Cb _____/gH
		<input type="checkbox"/> VDRL test <input type="checkbox"/> Pos
		<input type="checkbox"/> Other (if void):

Diagnosis (Check all that apply)

<input type="checkbox"/> Reportable diseases	<input type="checkbox"/> Malaria (not during pregnancy)	<input type="checkbox"/> Animal and Snake bites	<input type="checkbox"/> H
<input type="checkbox"/> Acute flaccid paralysis	<input type="checkbox"/> Malaria during pregnancy	<input type="checkbox"/> Asthma	<input type="checkbox"/> H
<input type="checkbox"/> Cholera	<input type="checkbox"/> Meningitis (Non meningococcal)	<input type="checkbox"/> Cardiovascular- High BP	<input type="checkbox"/> O
<input type="checkbox"/> Dysentery	<input type="checkbox"/> Onchocerciasis	<input type="checkbox"/> Cardiovascular- Other	<input type="checkbox"/> P
<input type="checkbox"/> Guinea worm	<input type="checkbox"/> Pelvic Inflammatory Disease	<input type="checkbox"/> Childhood mental disorder	<input type="checkbox"/> S
<input type="checkbox"/> Hemorrhagic fever	<input type="checkbox"/> Pneumonia	<input type="checkbox"/> Diabetes Mellitus	<input type="checkbox"/> D
<input type="checkbox"/> Measles	<input type="checkbox"/> Schistosomiasis	<input type="checkbox"/> Epilepsy	<input type="checkbox"/> E
<input type="checkbox"/> Meningitis (Meningococcal)	<input type="checkbox"/> Sleeping Sickness	<input type="checkbox"/> GI disorders (non infective)	<input type="checkbox"/> G
<input type="checkbox"/> Plague	<input type="checkbox"/> STI	<input type="checkbox"/> Injuries- Road traffic accidents	<input type="checkbox"/> I
<input type="checkbox"/> Rabies	<input type="checkbox"/> Tetanus (over 24 days ago)	<input type="checkbox"/> Injuries- Trauma of other origin	<input type="checkbox"/> O
<input type="checkbox"/> Tetanus (0-24 days ago)	<input type="checkbox"/> Typhoid Fever	<input type="checkbox"/> Malnutrition- low weight for age	<input type="checkbox"/> M
<input type="checkbox"/> Yellow Fever	<input type="checkbox"/> Urinary Tract Infections (UTI)	<input type="checkbox"/> Malnutrition- severe	<input type="checkbox"/> N
<input type="checkbox"/> Infectious Disease	<input type="checkbox"/> Tuberculosis	<input type="checkbox"/> Mental Illness- Anxiety	<input type="checkbox"/> A
<input type="checkbox"/> AIDS/HIV	<input type="checkbox"/> New case - No prior TB treatment	<input type="checkbox"/> Mental Illness- Depression	<input type="checkbox"/> D
<input type="checkbox"/> Cough or Cold (no pneumonia)	<input type="checkbox"/> New case - Previous TB treatment	<input type="checkbox"/> Mental Illness- Mania	<input type="checkbox"/> M
<input type="checkbox"/> Diarrhea- Acute	<input type="checkbox"/> Known TB Case - Med Refill	<input type="checkbox"/> Mental Illness- Schizophrenia	<input type="checkbox"/> S
<input type="checkbox"/> Diarrhea- Persistent	<input type="checkbox"/> Non Infectious Diseases	<input type="checkbox"/> Mental Illness- Other	<input type="checkbox"/> O
<input type="checkbox"/> Intestinal worms	<input type="checkbox"/> Alcohol and drug abuse	<input type="checkbox"/> Maternal and Perinatal Diseases	<input type="checkbox"/> P
<input type="checkbox"/> Leprosy	<input type="checkbox"/> Anemia	<input type="checkbox"/> Abortion	<input type="checkbox"/> B

Treatment (Check all that apply)

Drug	Dose	Drug
Antimalarial		Other Drugs
<input type="checkbox"/> Coartem		<input type="checkbox"/> Aspirin
<input type="checkbox"/> Quinine		<input type="checkbox"/> Cough Suction
<input type="checkbox"/> Chloroquine		<input type="checkbox"/> Dexamethasone
<input type="checkbox"/> Amodiaquine		<input type="checkbox"/> Diclofenac
<input type="checkbox"/> SP		<input type="checkbox"/> Folic Acid
<input type="checkbox"/> Artesunate		<input type="checkbox"/> Gentian violet
<input type="checkbox"/> Dexamethasone		<input type="checkbox"/> Hydrocortisone
Antibiotics		<input type="checkbox"/> Ibuprofen
<input type="checkbox"/> Albendazole		<input type="checkbox"/> Magnesium
<input type="checkbox"/> Amoxicillin		<input type="checkbox"/> Multivitamins
<input type="checkbox"/> Chloramphenicol		<input type="checkbox"/> Nystatin
<input type="checkbox"/> Ciprofloxacin		<input type="checkbox"/> Paracetamol
<input type="checkbox"/> Chloraxils		<input type="checkbox"/> Phenytoin
<input type="checkbox"/> Cotrimoxazole		<input type="checkbox"/> Pitavastatin
<input type="checkbox"/> Doxycycline		<input type="checkbox"/> Rifampin
<input type="checkbox"/> Erythromycin		<input type="checkbox"/> Sulfamonomethoxazole
<input type="checkbox"/> Gentamicin		<input type="checkbox"/> Vit. B group
<input type="checkbox"/> Metronidazole		Other
<input type="checkbox"/> Metronidazole		Other
<input type="checkbox"/> PFF		Other
<input type="checkbox"/> Tetracycline		Other
<input type="checkbox"/> Xopen		Other

Referrals and additional notes

Admitted to ward Notes TB Drug Regime

Referred to HIV care Initial Phase CRHE CRCS CRG

Referred for TB care Continuation Phase CRH

Referred for other services CRH

Patient Record Form

Clinic _____

Date _____	OPD Number _____	Patient's Last Name _____	First Name _____	New attendance <input type="checkbox"/> Yes <input type="checkbox"/> No
Parish _____	Village _____	Age: _____ Yrs _____ Mos	Sex <input type="checkbox"/> Male <input type="checkbox"/> Female	Weight _____ kg

History & Exam Findings

Fever or history of fever? Yes No History of cough > 2 weeks? Yes No (BOTH these questions must be completed)

<input type="checkbox"/> BS for Malaria <input type="checkbox"/> Pos <input type="checkbox"/> Neg	<input type="checkbox"/> HIV test <input type="checkbox"/> CTDR <input type="checkbox"/> CTR	<input type="checkbox"/> TB exam
Parasite density: _____ (if positive)	HIV Lab number: _____	1 st smear <input type="checkbox"/> Pos <input type="checkbox"/> Neg (today's date)
<input type="checkbox"/> RDT for Malaria <input type="checkbox"/> Pos <input type="checkbox"/> Neg		2 nd smear <input type="checkbox"/> Pos <input type="checkbox"/> Neg Date: _____
Malaria Lab number: _____		3 rd smear <input type="checkbox"/> Pos <input type="checkbox"/> Neg Date: _____
<input type="checkbox"/> Sput ordered - Results:	<input type="checkbox"/> Urinalysis ordered - Results:	TB Lab number: _____
		<input type="checkbox"/> Cb _____/gH

Diagnosis (Check all that apply)

<input type="checkbox"/> Reportable diseases	<input type="checkbox"/> Malaria (not during pregnancy)	<input type="checkbox"/> Animal and Snake bites	<input type="checkbox"/> Hemorrhage during pregnancy
<input type="checkbox"/> Acute flaccid paralysis	<input type="checkbox"/> Malaria during pregnancy	<input type="checkbox"/> Asthma	<input type="checkbox"/> High BP during pregnancy
<input type="checkbox"/> Cholera	<input type="checkbox"/> Meningitis (Non meningococcal)	<input type="checkbox"/> Cardiovascular- High BP	<input type="checkbox"/> Obstructed labour

Treatment (Check all that apply)

Drug	Dose	Drug	Dose
Antimalarial		Other Drugs	
<input type="checkbox"/> Coartem		<input type="checkbox"/> Aspirin	
<input type="checkbox"/> Quinine		<input type="checkbox"/> Cough Suction	
<input type="checkbox"/> Chloroquine		<input type="checkbox"/> Dexamethasone	
<input type="checkbox"/> Amodiaquine		<input type="checkbox"/> Diclofenac	
<input type="checkbox"/> SP		<input type="checkbox"/> Folic Acid	
<input type="checkbox"/> Artesunate		<input type="checkbox"/> Gentian violet	
<input type="checkbox"/> Dexamethasone		<input type="checkbox"/> Hydrocortisone	
Antibiotics		<input type="checkbox"/> Ibuprofen	
<input type="checkbox"/> Albendazole		<input type="checkbox"/> Magnesium	
<input type="checkbox"/> Amoxicillin		<input type="checkbox"/> Multivitamins	
<input type="checkbox"/> Chloramphenicol		<input type="checkbox"/> Nystatin	
<input type="checkbox"/> Ciprofloxacin		<input type="checkbox"/> Paracetamol	
<input type="checkbox"/> Chloraxils		<input type="checkbox"/> Phenytoin	
<input type="checkbox"/> Cotrimoxazole		<input type="checkbox"/> Pitavastatin	
<input type="checkbox"/> Doxycycline		<input type="checkbox"/> Rifampin	
<input type="checkbox"/> Erythromycin		<input type="checkbox"/> Sulfamonomethoxazole	
<input type="checkbox"/> Gentamicin		<input type="checkbox"/> Vit. B group	
<input type="checkbox"/> Metronidazole		Other	
<input type="checkbox"/> Metronidazole		Other	
<input type="checkbox"/> PFF		Other	
<input type="checkbox"/> Tetracycline		Other	
<input type="checkbox"/> Xopen		Other	

Referrals and additional notes


Admitted to ward Notes TB Drug Regime (Check if prescribed)

Referred to HIV care Initial Phase CRHE CRCS CRG

Referred for TB care Continuation Phase CRH

Referred for other services CRH

ISTC Quality Indicators



Data website: <http://www.mu-ucsf.org/tb>

UGANDA TB SURVEILLANCE PROJECT | Data Management Website

[Home](#) | [View Data](#) | [View Quarterly Reports](#) | [muucsf.org](#) | [idrc-uganda.org](#)

Select Criteria

Site: *(use 'Ctrl' key to select multiple sites)*

- Aduku
- Kamwezi
- Kasambya
- Kihihi
- Nagongera**
- Walukuba

Indicator:

% AFB Ordered if Cough \geq 2 weeks

From:

Q1 2009

To:

Q4 2010

Graph type:


Line Bar

Frequency:

Quarterly Yearly

[View/Update Graph](#)

[View data in alternate format](#)



Outline

- Background and specific aims
- Overview of study setting
- **Methods/Results to date: Aims 1-3**
- Conclusions and Future Directions

Aim 1: “Define quality gap”

- Prospective study Jan-Dec 2009
- Descriptive analysis of ISTC quality indicators
 - Point estimates (95% CI), by quarter
 - Change over time
- Study population

N (range)	62,909
Female, % (95% CI)	70 (69-71)
Age, median (IQR)	29 (21-40)

TB Suspect
Evaluation
Algorithm

Total episodes of care

Cough \geq 2 weeks

Sputum AFB Ordered

Sputum AFB Completed

\geq 1 Positive | \geq 2 Negatives

AFB Smear-Positive

TB Treatment

Indicator

Proportions*, by quarter

Q1

14,852

365
2.5%

1

75
21%

2

55
73%

7
13%

3


5
71%

**Cumulative Probability of Diagnosing
and Treating Smear-Positive TB**


11%

*Proportions account for clustering by site, and therefore differ from the proportions that would be calculated directly from the numbers displayed in the table.


Indicator 1: Referred for TB exams




Indicator 2: Completed TB exams




Indicator 3: Treated if AFB-positive



Summary Indicator



Gender disparities




* Adjusted for site and date of clinical encounter. Reference group is male gender.

Aim 1: Summary

- Poor adherence to ISTC at baseline
- Modest improvements → 4-fold increase in TB case detection (7 to 25 cases/quarter)
- High yield of smear examination (13-21%)
- Strong need for strategies to enhance ISTC implementation

Aim 2: “Understand quality gap”

- Conceptual Framework: Theory of Planned Behavior




- Data collection
 - Key informant interviews
 - Semi-structured surveys
 - Field Observation
- Analysis
 - Transcribe interviews, surveys, field notes
 - Apply standard coding scheme to transcripts

Aim 2: Preliminary findings

Variable	Recurring themes
Knowledge/ Attitudes	<ul style="list-style-type: none">• Lack of familiarity with ISTC• Minimal opportunities for CME/training updates
Subjective Norms	<ul style="list-style-type: none">• Inconsistent support/guidance from clinic supervisors and the NTP• Tendency to focus on high suspicion patients• Competing important health concerns (e.g., malaria, HIV/AIDS)
Behavioral Control/ Self-efficacy	<ul style="list-style-type: none">• Belief that patients will not complete diagnostic evaluation• Inability to track patients who are lost-to-follow-up• Belief that successful TB screening reduces risks for rest of community
Ecologic/ Structural Factors	<ul style="list-style-type: none">• Stock-outs of reagents, supplies, medications• Low motivation – low salaries, delays in payments• Substandard workflow and recordkeeping• Lack of feedback to guide improvement

Aim 3: “Improve quality gap”




- ISTC training
 - Interactive, case-based training modules
- Single-specimen LED microscopy*
 - Facilitate same-day TB evaluation and treatment
- Performance feedback
 - Facilitate continuous quality improvement

Study Design


- Pilot study – quantify impact of each component
 - Interrupted time series design
 - Primary Outcome: TB case detection

- Secondary Outcomes
 - ISTC quality indicators
 - Behavioral model inputs

- Predictors
 - Intervention component
 - Time trend
 - Patient- and site-level factors



Interrupted Time Series Design



KEY DESIGN FEATURES FOR PILOT STUDY

- Intervention components evaluated individually
- Sequential introduction of intervention at study sites (order selected randomly)
- Outcomes measured at multiple time points
- Utilize statistical methods (GEE, mixed models) to account for clustered data
- All sites receive intervention by end of the study

KEY LIMITATIONS

- Hawthorne effect
- Generalisability

Lessons Learned

- Poor quality of TB suspect evaluation is likely a major contributor to low case detection rates
- Methods to improve the quality of TB suspect evaluation are likely to enhance the impact of better diagnostics
- Implementation science
 - External assessment often different from reality on the ground
 - Theoretical frameworks can help identify secondary outcomes that help explain intervention efficacy or lack of efficacy
 - Quasi-experimental designs can improve upon the standard before-and-after comparison

Acknowledgements

Phil Hopewell

Laurence Huang

Luke Davis

Grant Dorsey

Cecily Miller

Joshua Vasquez

Erin Crawford

Latifat Alli

Pratheepa Sivaswarupan

Asa Tapley

Achilles Katamba

Moses Kamyia

Asadu Sserwanga

Stella Kakeeto

Fred Kizito

Anne Gasasira

Geoff Lavoy

Ruth Kigozi

Francis Adatu

Moses Joloba

Questions/Comments

